Related Articles
MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection
Mutations in the STAT1‑interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy
Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy
Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review)
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group